Calling attention to a podcast from Wilmer Eye – Diagnosis Glaucoma. Drs. Mona Kaleem and Harry Quigley talk with Dr. Gary Novack about the Drug Development Process for new pharmacological treatments for glaucoma. In episode 43, discussed are the development and FDA approval process of eye drop medications for glaucoma. Towards the end of the podcast, there is discussion about 2023 recalled eye drops
Dr. Novack was selected to be a fellow of the Association for Ocular Pharmacology and Therapeutics.
The Association for Ocular Pharmacology and Therapeutics is a global organization for scientists and individuals from all disciplines related to ocular pharmacology and its therapeutic applications. Fellows of AOPT are nominated by their peers based upon service to the Association and its publication, “Journal of Ocular Pharmacology and Therapeutics”.
Dr. Novack gave a lecture at the Kellogg Eye Center of the School of Medicine at the University of Michigan. The topic was “Contaminated Eye Drops: What is going on”? He described the ongoing issue with contamination and infection, what to do for patients, and the impact of this issue on the larger field of ophthalmic pharmaceuticals.
In this, my 40th ARVO annual meeting, I was able to share science, thoughtful discussions, and social encounters with friends and colleagues. While we are no longer on the beach in shorts, the spirit of Sarasota can still be seen in respectful, impactful discourse.
I call attention to this paper of mine just published in Eye & Contact Lens together with colleagues Drs. Kathryn Richdale, Erin Tomiyama and Mark Bullimore – a survey of the variability of atropine formulation, sterility and stability testing and storage requirements for compounded low dose atropine for myopia prevention.
Dr. Gary Novack presented an invited talk on “Why are there not more new glaucoma drugs” at the August meeting of the Glaucoma Research Society. The Glaucoma Research Society is a public interest, non-profit scientific association of outstanding glaucoma researchers that provides a forum to discuss and stimulate compelling or innovative research to prevent glaucoma-related disability worldwide. It is limited to 100 members worldwide. Dr. Novack is a long-time member.
In May, Dr. Novack was part of a UC Davis Department of Ophthalmology & Vision Science weekend Continuing Medical Education course in Napa. He presented issues surrounding off-label use and compounded medications in ophthalmology. He also discussed generic vs. branded products.
Dr. Novack was featured in a spotlight on ARVO members in a May 2022 posting of The Ophthalmologist entitled “Captain’s Log”, the reported focused on Dr. Novack’s answer to a query about an analogy for his work. Novack said “…like Captain James T. Kirk in the Star Trek Original Series “Corbomite Maneuver”, episode, I use available information to take strategic directions and optimize resources. He also gives to his “…parents, who were first generation to college, for providing me the education (together with the University of California) to enable me to reach my adolescent goal of being a scientist. I also credit my family for giving me support and fulfillment throughout my life.”
Dr. Gary Novack presented two posters at the May 2022 ARVO conference in Denver. One of these was presented in the Cornea section on preclinical data on a new investigative potential treatment for dry eye disease. The other was presented in the retina section on Phase 3 studies of a new topical anesthetic for use in the office for various procedures including intravitreal dosing.
Gonzalez VH, Wirta DL, Uram M, Schupp A, Widmann M, Novack GD. Two Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Studies of the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution 8% (AG-920)
Park LC, Gharat L, Park, K, Alam J, Yu Z, Hu Y, de Paiva CS, Novack GD. Pflugfelder SC. Dry Eye: Evaluation of novel YP-P10 Peptide in animal models of inflammatory dry eye disease.
With a recent product approval, Dr. Novack has now made substantial contributions to 60 approved products during his career. As he noted in an editorial, half of “Pharmacology” is “Therapeutics” – providing better ways to treat patients. Please see “Key Roles” on the PharmaLogic website.